Sitting on a Cash Pile 6.0? BioScience on Fire

#cash #bioscience #StrongBuy


AnaptysBio Inc. (NASDAQ:ANAB) broke out on 14 October at 20.37, and confirmed on 27 October at 27.93.

Thus, garnering a Strong Buy with a target price of 100 as all Key technical indicators have turned Very Bullish.

The Key support is at 20.22 and there is no overhead resistance.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.

The company’s products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation.

AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; and collaboration with Celgene Corporation.

The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006.

AnaptysBio, Inc. was founded in Y 2005 and is HQ’d in San Diego, California.

Have a healthy day, Keep the Faith!


#AnaptysBio#bioscience#cash pile#immuno-oncology#inflammation#NABA#resistance#Strong Buy#support#very bullish